Virios Q2 net loss $1.4M ($0.08/share); cash $4.6M; FDA IMC-1 toxicology adequate; pK study planned

Dogwood Therapeutics, Inc.

2023-Q1 EPS reported -$0.16

Net loss $1.4M ($0.08 per share) vs $3.7M ($0.44) in Q2 2022; R&D down to $0.6M, G&A down to $0.9M.
Cash $4.6M at June 30, plus $1.4M raised via July Sales Agreement; runway at least 12 months.
FDA indicates IMC-1 chronic toxicology program adequate to support Phase 3 fibromyalgia study.
Pk/food-effect study planned for H2 2023; first Phase 3 FM study enrollment targeted for mid-2024.
IMC-2 Long-COVID: new double-blind placebo-controlled study with Bateman Horne Center; FDA meeting to discuss Phase 2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dogwood Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $1.4 million, EPS $0.08 basic and diluted net loss per share.

Period: the second quarter ended June 30, 2023
Net income: $1.4 million
EPS: $0.08 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $1.4 million, or $0.08 basic and diluted net loss per share

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.